Ep. 522 Advancements in Treatment of Metastatic Ocular Melanoma with Dr. Altan Ahmed and Dr. Sid Padia

13 snips

Mar 4, 2025

In this enlightening discussion, Dr. Altan Ahmed from Moffitt Cancer Center and Dr. Sid Padia from UCLA delve into the innovative HEPZATO treatment for liver metastases from uveal melanoma. They explore patient selection for clinical trials and the intricacies of the treatment procedure. The conversation highlights the importance of teamwork in optimizing workflow and drug dosing, as well as the need for ongoing research to address current gaps. They also discuss future applications for HEPZATO in treating other malignancies, promising new hope for patients.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

ADVICE

Patient Selection

Select patients with liver-dominant uveal melanoma, ECOG 0-1, and good liver function.
Exclude patients with cirrhosis or who can't tolerate general anesthesia.

ANECDOTE

Pharmacy Coordination Challenges

Initial pharmacy coordination can be difficult, with discrepancies between estimated and actual times.
With practice, timing improves, allowing for efficient drug delivery and minimizing filter degradation.

INSIGHT

Uveal Melanoma Treatment Landscape

Uveal melanoma patients have limited treatment options beyond first-line therapies.
Hepzato offers a promising intervention, particularly given the lack of effective second-line treatments.

Get the Snipd Podcast app to discover more snips from this episode

Get the app